

Clinical Presentations and Management Differences of COPD and Pulmonary Edema

Cline: ch. 25 ; ch. 37
Brady pp 583; 694
(+/- other standard
paramedic text)

EMC 360

Objectives

Upon completion of this lecture you should be able to discuss :

- Discuss the common clinical occurrence of having to distinguish "heart vs lung" in acutely ill patients
- Compare and contrast COPD and Pulmonary Edema in their clinical presentation regarding:
 - History (present illness, medications)
 - Physical findings
 - Management differences

EMC 360

Distinguishing "Heart vs Lung" in Acutely Ill Patients

When faced with a patient in respiratory distress, the emergency clinician is:

- Focused on the initial assessment and intervention
- **Not** primarily focused on making a specific diagnosis
- Aware that the initial management of COPD and pulmonary edema have many similarities but also a few significant differences

EMC 360

Distinguishing "Heart vs Lung" in Acutely Ill Patients

Assessment pitfalls:

- All desaturated patients are **not** "lungers"
- "All that wheezes is **not** asthma"
[nor COPD with asthma]
- "All that wheezes does **not** need Albuterol"
- "It's dangerous to initiate therapy before xray and lab work"
- All cardiac asthma patients are **not** hypertensive
- All COPDers are **not** dry and non-diaphoretic

EMC 360

Distinguishing "Heart vs Lung" in Acutely Ill Patients

Assessment pitfalls:

- "All that wheezes is **not** asthma"
- Adult wheezing, has many causes; in a "CUPS" assessment, a critical or unstable patient often has wheezing - due to RAD
 - Both COPD and Pulmonary Edema trigger RAD

Treatment pitfall:

- Failing to treat bronchospasm because: "Heart patients (Pul Ed) must not be given Albuterol"

EMC 360

Acutely Ill Patients with CHF

Diagnosis before therapy ??

- No; the diagnosis is not needed before initial therapy: all critical or unstable medical patients receive: ABCDE / O2 M3 Bld IV Glu
- Both COPD and Pulmonary Edema receive the same initial therapy except high-flow O2
- CHF diagnosis (during therapy) is based on:
 - clinical criteria

EMC 360

Acutely Ill Patients with CHF

- CHF diagnosis (after therapy has been initiated) is based on clinical criteria [Framingham; others]
 - History and Physical
 - Objective evidence of ventricular failure
 - Response to therapy
- Diagnosis can be difficult :
 - In a hurry
 - Without an xray
 - In patients who also have lung disease (COPD, pneumonia)

EMC 360

Distinguishing “Heart vs Lung” and Treating Acute CHF

New rapid,

- Test for distinguishing “heart vs lung”
 - High BNP levels help distinguish CHF from other causes of acute dyspnea
- At the “point of care” [like an accucheck ...?]
- BNP levels :
 - Non-CHF dyspnea (pneumonia, COPD/RAD,...) : 40
 - CHF : 1000 + [1076 +/- 138 pg/ml]

EMC 360

Distinguishing “Heart vs Lung” in Acute Dyspnea

Heart

Lung

causes:

- | | |
|---|--|
| <ul style="list-style-type: none"> • Pulmonary Edema (LCHF, decompensated) | <ul style="list-style-type: none"> • Asthma • COPD • Mimics <ul style="list-style-type: none"> – FBAO – Anaphylaxis – Pneumonia |
|---|--|

EMC 360

Distinguishing “Heart vs Lung” in Acute Dyspnea

Heart

Lung

cc:

- | | |
|---|--|
| <ul style="list-style-type: none"> • SOB • +/- chest pain • Sudden onset | <ul style="list-style-type: none"> • SOB • Rare chest pain • Sudden onset
[chronic dz, which suddenly worsened] |
|---|--|

EMC 360

Distinguishing “Heart vs Lung” in Acute Dyspnea

Heart

Lung

Hx:

- | | |
|--|--|
| <ul style="list-style-type: none"> • CAD / CHF • MI ; CABGS • Exertion • Off diuretic / increased salt • Dialysis patient | <ul style="list-style-type: none"> • Lung Dz ; smoker • recent hospitalization • Exercise / DOE • Environment <ul style="list-style-type: none"> – air pollution – pollen |
|--|--|

EMC 360

Distinguishing “Heart vs Lung” in Acute Dyspnea

Heart

Lung

Hx: Meds:

- | | |
|---|--|
| <ul style="list-style-type: none"> • heart meds <ul style="list-style-type: none"> – NTG – ACE I – B blocker • lasix, K+ • ASA • Statin | <ul style="list-style-type: none"> • Home O2 • Inhalers <ul style="list-style-type: none"> – albuterol – atrovent • Prednisone |
|---|--|

EMC 360

Heart

Lung

PE

Across the Room

- **Upright**
- Agitated

- restless

Airway:

- Pink frothy

- “sniff”; pursed lips

Breathing:

- +/- wheezing

- +/- wheezing

EMC 360

Heart

Lung

PE

Circ.:

- **Pale, cool, clammy**

- Dry; +/- cyanotic

Vitals:

- **O2 sat:** less than 86%

- O2 sat: ~ 90%

- **BP:** **250/140**

- Normal or slightly elevated

- **HR:** ST or A-fib with RVR

- slightly elevated

- **RR:** increased

- Increased

- **T** **cold / clammy**

- slight fever

EMC 360

Heart

Lung

CHEST:

- wheezes + **wet rales**

- wheezing or quiet

CV:

- “S₃; S₄ “...if SBP 220+

- distant heart tones (barrel chest)

Treatment

- High flow O2 NRB

- low flow O2, unless in respiratory failure

EMC 360

Heart

Lung

Treatment:

- **NTG** 0.4 - 0.8 mg **SL**

- Albuterol 1.25-5 mg HHN

- **NTG** 2" paste

- Ipratropium 500 mc HHN

- **NTG** IV 10-50 mc/min

- Mg 1-2 gram IV

- Lasix 80-120 mg IV

- Solumedrol 125mg IV

- Morphine 4 mg IV (controversial)

- BiPAP, if O2 Sat still not 90% after NRB

- CPAP/BPAP, if O2 Sat still not 95% after NRB

- ET (as large* as possible):

- Albuterol (as per local protocol). [**Not** epi.]

- ALOC +/- exhaustion

- ALOC +/- fatigue: ET

- Hypercarbia / acidosis

- BNP 2 MIC / KG IV bolus

- If O2 Sat still below 90% after above therapies

* large ET aids weaning, suctioning, bronchoscopy, ventilating

EMC 360

Distinguishing “Heart vs Lung” and Treating Acute CHF

BNP in CHF :

- New rapid, inexpensive test for CHF diagnosis and prognosis
- Test for distinguishing “heart vs lung”
 - High BNP levels help distinguish CHF from other causes of acute dyspnea
- At the “point of care” [like an accucheck ...?]
- BNP levels :
 - Non-CHF dyspnea (pneumonia, COPD/RAD,...) : 40
 - CHF : 1000 + [1076 +/- 138 pg/ml]

EMC 360

BNP in Acute CHF

- High BNP level:
 - marker for LV dysfunction
- When LV is stressed and stretched
 - the myocyte (by activating a gene transcription) responds by producing a small protein [hormone]
- BNP neurohormone effects
 - of renin-angiotensin-aldosterone system (which is also activated by LV dysfunction)

EMC 360

BNP in Acute CHF

- Increased levels of BNP (and levels of other natriuretic peptides, ANP and CNP)
 - Cause diuresis, vasodilatation, and natriuresis
 - Reduce preload
 - Reduce afterload

EMC 360

IV BNP for Treating Acute CHF

IV BNP, nesiritide (Natrecor) :

- MOA:
 - Sodium excretion (natriuresis)
 - Diuresis
 - Vasodilation
- May be indicated for acute decompensated CHF
- Response to treatment can be assessed
- Dose : 2 mcg / kg IV bolus ; then
0.01 mcg / kg / min IV continuous drip

EMC 360

BNP in Acute CHF

- CHF pathophysiology causes elevated BNP
- BNP blood sampling can accurately detect CHF
- IV BNP can be as effective as treatment for CHF ⁽¹⁾
- IV BNP is as effective as standard treatment ⁽¹⁾
- BNP levels can be used as a :
 - test for response to therapy
 - predictive marker for limitation and for sudden cardiac death in CHF patients ⁽²⁾

(1) Calucci *NEJM* 2000;334:248-253

(2) Bergen, *Circulation*

EMC 360

Summary

We have discussed :

- Common clinical similarities in the “heart vs lung” acutely ill patient
- Comparative pulmonary edema vs COPD similarities and differences in their presenting: Hx, PE findings, management
- A few treatments that are different, that are relatively contraindicated, or that are even absolutely contraindicated in one or the other.

EMC 360